%0 Journal Article %T Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells. %+ Signaling and Development Laboratory %+ Régulations cellulaires et oncogenèse (RCO) %+ Institut de génétique et biologie moléculaire et cellulaire (IGBMC) %+ FIRC %+ Melanogenix Group %+ Ludwig Institute for Cancer Research %A Goodall, Jane %A Carreira, Suzanne %A Denat, Laurence %A Kobi, Dominique %A Davidson, Irwin %A Nuciforo, Paolo %A Sturm, Richard, A. %A Larue, Lionel %A Goding, Colin, R. %< avec comité de lecture %@ 0008-5472 %J Cancer Research %I American Association for Cancer Research %V 68 %N 19 %P 7788-94 %8 2008-10-01 %D 2008 %R 10.1158/0008-5472.CAN-08-1053 %M 18829533 %Z Life Sciences [q-bio]/Biochemistry, Molecular BiologyJournal articles %X The origin of tumor heterogeneity is poorly understood, yet it represents a major barrier to effective therapy. In melanoma and in melanocyte development, the microphthalmia-associated transcription factor (Mitf) controls survival, differentiation, proliferation, and migration/metastasis. The Brn-2 (N-Oct-3, POU3F2) transcription factor also regulates melanoma proliferation and is up-regulated by BRAF and beta-catenin, two key melanoma-associated signaling molecules. Here, we show that Brn-2 also regulates invasiveness and directly represses Mitf expression. Remarkably, in melanoma biopsies, Mitf and Brn-2 each mark a distinct subpopulation of melanoma cells, providing a striking illustration of melanoma tumor heterogeneity with implications for melanoma therapy. %G English %L inserm-00350760 %U https://inserm.hal.science/inserm-00350760 %~ INSERM %~ CNRS %~ UNIV-STRASBG1 %~ IGBMC %~ UNIV-STRASBG %~ FNCLCC %~ CURIE %~ PSL %~ SITE-ALSACE %~ INSTITUT-CURIE-PSL %~ TEST3-HALCNRS